- Home
- DTST vs OTLK Comparison
DTST vs OTLK Comparison
Compare DTST & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTST | OTLK |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 38.7M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | DTST | OTLK |
|---|---|---|
| Price | $4.05 | $0.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 9.6K | ★ 1.2M |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,425.11 |
| Revenue Next Year | N/A | $129.89 |
| P/E Ratio | $2.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $0.38 |
| 52 Week High | $5.44 | $3.39 |
Technical Indicators
Market Signals| Indicator | DTST | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 40.90 |
| Support Level | $3.74 | $0.39 |
| Resistance Level | $4.37 | $0.46 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 32.26 | 38.22 |
Price Performance
Historical ComparisonAbout DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.